We note the first day of dealing this morning for SkinBioTherapeutics (SBTX), a previous OptiBiotix (OPTI) division created by the acquisition of exclusive rights to IP developed by the University of Manchester. SBTX will focus on specific markets (e.g. cosmetics, infection control and dermatology) and in turn could operate in large multi-billion-dollar markets, which include skincare ($122bn), psoriasis ($7bn) and eczema ($4bn). As of this morning, OPTI retains a 41.9% holding of SkinBioTher
05 Apr 2017
SkinBioTherapeutics (SBTX) listed on AIM
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SkinBioTherapeutics (SBTX) listed on AIM
OptiBiotix Health PLC (OPTI:LON) | 20.5 -0.1 (-2.4%) | Mkt Cap: 18.7m
- Published:
05 Apr 2017 -
Author:
Cavendish Research -
Pages:
2
We note the first day of dealing this morning for SkinBioTherapeutics (SBTX), a previous OptiBiotix (OPTI) division created by the acquisition of exclusive rights to IP developed by the University of Manchester. SBTX will focus on specific markets (e.g. cosmetics, infection control and dermatology) and in turn could operate in large multi-billion-dollar markets, which include skincare ($122bn), psoriasis ($7bn) and eczema ($4bn). As of this morning, OPTI retains a 41.9% holding of SkinBioTher